Local Anesthetic Properties of Prenylamine Mustafa G
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Gabab Regulation of Methamphetamine-Induced Associative Learning
Loyola University Chicago Loyola eCommons Dissertations Theses and Dissertations 2010 Gabab Regulation of Methamphetamine-Induced Associative Learning Robin Michelle Voigt Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_diss Part of the Pharmacology Commons Recommended Citation Voigt, Robin Michelle, "Gabab Regulation of Methamphetamine-Induced Associative Learning" (2010). Dissertations. 38. https://ecommons.luc.edu/luc_diss/38 This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 2010 Robin Michelle Voigt LOYOLA UNIVERSITY CHICAGO GABAB REGULATION OF METHAMPHETAMINE-INDUCED ASSOCIATIVE LEARNING A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL IN CANDIDACY FOR THE DEGREE OF DOCTOR OF PHILOSOPHY PROGRAM IN MOLECULAR PHARMACOLOGY & THERAPEUTICS BY ROBIN MICHELLE VOIGT CHICAGO, IL DECEMBER 2010 Copyright by Robin Michelle Voigt, 2010 All rights reserved ACKNOWLEDGEMENTS Without the support of so many generous and wonderful individuals I would not have been able to be where I am today. First, I would like to thank my Mother for her belief that I could accomplish anything that I set my mind to. I would also like to thank my dissertation advisor, Dr. Celeste Napier, for encouraging and challenging me to be better than I thought possible. I extend gratitude to my committee members, Drs. Julie Kauer, Adriano Marchese, Micky Marinelli, and Karie Scrogin for their guidance and insightful input. -
Specifications of Approved Drug Compound Library
Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format. -
Medical Review Officer Manual
Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs EFFECTIVE OCTOBER 1, 2010 Note: This manual applies to Federal agency drug testing programs that come under Executive Order 12564 dated September 15, 1986, section 503 of Public Law 100-71, 5 U.S.C. section 7301 note dated July 11, 1987, and the Department of Health and Human Services Mandatory Guidelines for Federal Workplace Drug Testing Programs (73 FR 71858) dated November 25, 2008 (effective October 1, 2010). This manual does not apply to specimens submitted for testing under U.S. Department of Transportation (DOT) Procedures for Transportation Workplace Drug and Alcohol Testing Programs (49 CFR Part 40). The current version of this manual and other information including MRO Case Studies are available on the Drug Testing page under Medical Review Officer (MRO) Resources on the SAMHSA website: http://www.workplace.samhsa.gov Previous Versions of this Manual are Obsolete 3 Table of Contents Chapter 1. The Medical Review Officer (MRO)........................................................................... 6 Chapter 2. The Federal Drug Testing Custody and Control Form ................................................ 7 Chapter 3. Urine Drug Testing ...................................................................................................... 9 A. Federal Workplace Drug Testing Overview.................................................................. -
Educational Commentary – Testing for Amphetamines and Related Compounds
EDUCATIONAL COMMENTARY – TESTING FOR AMPHETAMINES AND RELATED COMPOUNDS Learning Outcomes Upon completion of this exercise, participants will be able to: • list amphetamine-like compounds that may be detected by immunoassay screening tests for amphetamines. • describe the 3 types of amphetamine immunoassays based on their antibody specificity. • discuss common causes of false-positive results when testing for amphetamines. Correct interpretation of testing results for amphetamines and related compounds is dependent on many factors including an understanding of the nomenclature, structure, and metabolism of these compounds. The class of phenethylamine compounds having varying degrees of sympathomimetic activity include amphetamine, methamphetamine, and many other compounds known by several names including amphetamines (as a group), designer drugs often grouped together as ecstasy [3,4- methylenedioxymethamphetamine (MDMA); 3,4-methylenedioxyamphetamine (MDA), and 3,4- methylenedioxy-N-ethylamphetamine (MDEA)], and sympathomimetic amines including ephedrine, pseudoephedrine, and phenylpropanolamine found in over-the-counter (OTC) medications. Amphetamine, a primary amine, and methamphetamine, a secondary amine, have a stereogenic center and have enantiomers or optical isomers designated d (or +) for dextrorotatory and l (or -) for levorotatory. In general, the d isomers are the more physiologically active compounds, but pharmaceutical preparations may consist of either isomer or a mixture of both isomers. When the mixture contains equal concentrations of the 2 enantiomers, it is known as a racemic mixture. The existence of enantiomers for amphetamines creates analytical and interpretative problems. Immunoassay Screening The primary screening methods for detecting amphetamines are immunoassays. The structural similarity to amphetamine or methamphetamine of the compounds previously mentioned makes it difficult to produce antibodies specific for amphetamine, methamphetamine, or both. -
Download Product Insert (PDF)
Product Information Fendiline (hydrochloride) Item No. 17295 CAS Registry No.: 13636-18-5 Formal Name: γ-phenyl-N-(1-phenylethyl)- benzenepropanamine, monohydrochloride MF: C23H25N • HCl FW: 351.9 N Purity: ≥95% H Stability: ≥2 years at -20°C Supplied as: A crystalline solid • HCl Laboratory Procedures For long term storage, we suggest that fendiline (hydrochloride) be stored as supplied at -20°C. It should be stable for at least two years. Fendiline (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the fendiline (hydrochloride) in the solvent of choice. Fendiline (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of fendiline (hydrochloride) in these solvents is approximately 15, 30, and 20 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of fendiline (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of fendiline (hydrochloride) in PBS, pH 7.2, is approximately 0.1 mg/ml. We do not recommend storing the aqueous solution for more than one day. α Fendiline is an 2-adrenergic receptor antagonist (Kd = 2.6 µM) and an L-type calcium channel blocker (IC50 = 17 µM) well-known for its coronary vasodilator effects.1-4 Fendiline has recently been reported to inhibit K-Ras plasma membrane localization (IC50 = 9.64 µM), which prevents K-Ras signal transduction and blocks the proliferation of K-Ras-transformed tumor cells.5 References 1. -
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
NINDS Custom Collection II
ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC -
MRO Manual Before 2004
Note: This manual is essentially the same as the 1997 HHS Medical Review Officer (MRO) Manual except for changes related to the new Federal Custody and Control Form (CCF). The appendix has also been deleted since the new Federal Custody and Control Form is available as a separate file on the website. Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs for use with the new Federal Drug Testing Custody and Control Form (OMB Number 0930-0158, Exp Date: June 30, 2003) This manual applies to federal agency drug testing programs that come under Executive Order 12564 and the Department of Health and Human Services (HHS) Mandatory Guidelines. Table of Contents Chapter 1. The Medical Review Officer (MRO) ............................................................... 1 Chapter 2. Federal Drug Testing Custody and Control Form .......................................... 3 Chapter 3. The MRO Review Process ............................................................................ 3 A. Administrative Review of the CCF ........................................................................... 3 I. State Initiatives and Laws ....................................................................................... 15 Chapter 4. Specific Drug Class Issues .......................................................................... 15 A. Amphetamines ....................................................................................................... 15 B. Cocaine ................................................................................................................ -
Lidocaine Infusion for Analgesia MOA Pharmacology 1
Lidocaine Infusion for Analgesia MOA Pharmacology 1. Attenuation of proinflammatory effects: Ø Hepatic metabolism with high extraction ratio; Ø Blocks polymorphonuclear granulocyte priming, plasma clearance is 10 ml/kg/min13 reducing release of cytokines & reactive oxygen species1 Ø Adjust dose based on hepatic function and 2. Diminish nociceptive signaling to central nervous system: blood flow Ø Inhibition of G-protein-mediated effects2 Ø Renal clearance of metabolites Ø Reduces sensitivity & activity of spinal cord neurons Ø Context-sensitive half-time after a 3-day infusion is (glycine and NMDA receptor mediated)3,4 ∼20–40 min Ø Clinical effect of lidocaine tends to exceed the 5 3. Reduces ectopic activity of injured afferent nerves duration of the infusion by 5.5 times the half-life, supporting the putative preventive analgesia effect14 Perioperative Use Dosing Ø IV local anesthetic infusions have been used safely for pain control in the perioperative setting since the early 1950’s6,7 Infusion: 2mg/kg/hr (range 1.5-3 mg/kg/hr) Ø Reduce pain, nausea, ileus duration, opioid requirement, Loading dose: 1.5mg/kg (range 1-2 mg/kg) and length of hospital stay Ø Strongly consider bolus to rapidly achieve therapeutic concentration, otherwise steady state 9-12 Evidence for Specific Surgeries: reached in 4-8 hr Ø Strong: Open & laparoscopic abdominal; Reduces Max dose: 4.5 mg/kg postoperative pain, speeds return of bowel function, Ø Consider total dose from other local anesthetics reduces PONV, reduces length of hospital stay (e.g. regional anesthesia, periarticular injections, & Ø Moderate: Open prostatectomy, thoracic procedures, local infiltration) ambulatory surgery, and major spine; Reduces Continuous infusions up to 3 mg/kg/hr have been postoperative pain and opioid consumption shown to be safe Ø Moderate: Breast; Prevention of chronic postsurgical pain Ø Reduce infusion rate in patients with impaired Ø No benefit: Total abdominal hysterectomy, total hip drug metabolism & clearance (i.e. -
Local Anesthetic Toxicity: Prevention and Treatment
Local Anesthetic Toxicity: Prevention and Treatment John W. Wolfe, M.D. Staff Anesthesiologist Indiana University School of Medicine Indianapolis, Indiana John F. Butterworth, M.D. Chairman, Department of Anesthesia Indiana University School of Medicine Indianapolis, Indiana LESSON OBJECTIVES dine, and the site of injection on peak Upon completion of this lesson, the reader local anesthetic concentrations in blood. should be able to: 6. Describe the mechanism of local anes- 1. List the signs and symptoms of local thetic central nervous system toxicity. anesthetic toxicity. 7. Identify the risk factors for local anes- 2. Discuss the concept of "maximum safe thetic toxicity. doses of a local anesthetic." 8. Plan the treatment of local anesthetic- 3. Describe methods for reducing the risk of induced cardiac arrhythmias and cardiac local anesthetic toxicity. arrest. 4. Explain the treatment of local anes- 9. Describe the mechanism of local anes- thetic-related neurologic symptoms and thetic cardiovascular toxicity. toxic side effects. 10. Explain the dosage and proposed mech- 5. Discuss the effects of epinephrine, cloni- anism of lipid emulsion therapy. Current Reviews for Nurse Anesthetists designates this lesson for 1 CE contact hour in Clinical pharmacology/therapeutics. Introduction Mechanism of Cardiac and central nervous system (CNS) toxic Local Anesthetic Toxicity side effects of local anesthetics are relatively rare but potentially catastrophic complications of local and Local anesthetics normally produce their desired regional anesthesia. Fortunately, the likelihood of a effects on peripheral nerves by binding and inhibit- local anesthetic toxic event can be reduced by ad- ing voltage-gated sodium channels in neural cell herence to good technique. -
WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/337 (2006.01) A61K 31/48 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/395 (2006.01) A61K 31/51 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/4174 (2006.01) A61K 31/549 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/428 (2006.01) A61K 31/663 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/IB20 12/002768 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, 25 October 2012 (25.10.2012) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/552,922 28 October 201 1 (28. -
A Complete Toxicology Screening Procedure for Drugs and Toxic Compounds in Urine and Plasma Using LC-MS/MS
Application Note: 449 A Complete Toxicology Screening Procedure for Drugs and Toxic Compounds in Urine and Plasma Using LC-MS/MS Marta Kozak, Taha Rezai, Thermo Fisher Scientific, San Jose, CA Introduction Key Words Toxicology laboratories commonly use automated Scan Event 1 Scan Event 7 + Full Scan MS – Full Scan MS • ToxSpec immunoassays, gas chromatography-mass spectrometry Analyzer (GC-MS) and high pressure liquid chromatography-diode array detector (HPLC-DAD) techniques to perform • ToxID Software toxicology screening analyses. None of these techniques • LXQ Linear Ion are able to identify all the drugs and toxic compounds Trap that are potentially present in a sample. Implementation of liquid chromatography-mass spectrometry (LC-MS) for • Clinical toxicology screening provides specific and sensitive Toxicology analysis of drugs and toxic substances. The benefits of the • General LC-MS/MS screening methodology include a simple Unknown sample preparation procedure, ease of adding new Screening compounds to the screening method and fewer limitations based on compound volatility and thermal stability. In Scan Event 2-6 Scan Event 8-9 addition, Thermo Scientific ToxID automated toxicology + MS/MS on parent list – MS/MS on parent list screening software is able to automatically generate both Summary and Long Reports, avoiding the need for Figure 1: MS scan events manual analysis of each sample chromatogram. This application note describes the use of the Thermo Scientific LXQ ion trap mass spectrometer equipped with an ESI source and HPLC for identification of unknown compounds in human urine and human plasma. Step 1: Extract analytes from urine or plasma with SPE procedure Goal To develop a complete LC-MS/MS screening methodology which includes a sample preparation method, LC-MS Step 2: Analyze the samples method, spectra library, and data processing and reporting with LC-MS/MS method software.